News | February 18, 2022
AptarGroup reported 2021 sales at US $3.23 billion
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Evonik invests in start-up to improve patient recovery after open-chest surgery
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Subscribe To Our Newsletter & Stay Updated
